Please ensure Javascript is enabled for purposes of website accessibility
Free Article Join Over 1 Million Premium Members And Get More In-Depth Stock Guidance and Research

Why Endocyte, Unwired Planet, and LIN Media Are Today's 3 Best Stocks

By Sean Williams - Mar 21, 2014 at 5:15PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Geopolitical tensions drag down the S&P 500, while Endocyte, Unwired Planet, and LIN Media explode higher to end the week.

Heading into the weekend, investors had no large-scale economic data to rely on, and focused instead on persistent tensions between Russia and the rest of the world about its annexation of Crimea from Ukraine.

As a result of Russia's aggression to claim Crimea, the U.S. and EU have both imposed sanctions on Russia. These have the potential to slow down growth in an otherwise rapidly growing country. Were Russia to retaliate with sanctions of its own, it's quite possible that global growth prospects could tick down a bit, which wouldn't bode favorably for stocks.

Also, I believe the mixed reality of a QE3 taper is beginning to hit home with investors following Fed chairperson Janet Yellen's commentary earlier this week. The U.S. economy is doing better, as evidenced by the additional $10 billion taper down to $55 billion in economic stimulus each month. But the taper also signals the end of free money and a possible shift in lending rates, which the Fed may look to raise as early as next year. When rates begin to rise, it's quite possible that industries that are very reliant on low lending rates, such as homebuilders, could be hurting big time.

Despite hitting a fresh all-time intraday high, the broad-based S&P 500 dipped by 5.49 points (-0.29%) to close at 1,866.52, but still ended the week more than 1% higher than where it began.

The highlight of the day, though, went to biopharmaceutical company Endocyte (NASDAQ: ECYT), which skyrocketed 92.4% after announcing a duo of positive news. First. it announced that its phase 2b results for its TARGET trial evaluating the combination of vintafolide and docetaxel in treating non-small cell lung cancer (NSCLC) patients met its primary endpoint, and lowered the risk of disease worsening or death by 25% compared to the docetaxel arm by itself. Also, Endocyte received a positive opinion from the Committee for Medicinal Products for Human Use in the EU on Vynfinti (the EU name for vintafolide), and its companion diagnostics Folcepri and Neocepri for conditional marketing authorizations. These three positive opinions will now be reviewed by the European Commission. In addition to representing a solid win for Endocyte, it's a big positive for Merck ( MRK -1.55% ), which is Endocyte's licensing and marketing partner outside the United States.

Not to be outdone, small-cap intellectual property and licensing company Unwired Planet (NASDAQ: UPIP) soared 49.2% after announcing that it had sold a portfolio of patents to China's Lenovo for $100 million in cash, as well as agreed to a term-based license of Unwired's patent portfolio with Lenovo. The portfolio includes patents that relate to 3G and LTE mobile technologies, as well as other mobile patents, and should help Lenovo build on its push into mobile following its recent acquisition of Motorola Mobility from Google. For Unwired, it now gives the company fresh capital that can be deployed to buy or develop new technology patents.

Finally, multimedia company LIN Media (NYSE: LIN) soared 22.5% after it and Media General (NYSE: MEG) announced that they would be merging in a $2.6 billion deal to create the second-largest pure-play television broadcasting company. Under the terms of the deal, LIN shareholders can choose to receive either $27.82 per share in cash, or 1.5762 shares of the new holding company for each share of LIN that they own. The transaction will help the combined company reach 23% of all U.S. TV households with the expectation that cost synergies could reach $70 million annually after the third year post-merger. This looks like a smart move for these two companies, with media giants in general merging en masse of late. I still urge caution because the valuation of the combined entity may be a bit rich at the moment, but the deal should be a winner in the long run.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Merck & Co., Inc. Stock Quote
Merck & Co., Inc.
$72.28 (-1.55%) $-1.14

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 12/07/2021.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Our Most Popular Articles

Premium Investing Services

Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.